The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
The Role of the p53 Protein in Stem-Cell Biology and Epigenetic Regulation
Abstract
The p53 protein plays a passive and an active role in stem cells. The transcriptional activities of p53 for cell-cycle arrest and DNA repair are largely turned off in stem cells, but there is some indication that long-term stem-cell viability may require other p53-regulated functions. When p53 is activated in stem cells, it stops cell division and promotes the commitment to a differentiation pathway and the formation of progenitor cells. In the absence of any p53 activity, stem-cell replication continues and mistakes in the normal epigenetic pathway occur at a higher probability. In the presence of a functionally active p53 protein, epigenetic stability is enforced and stem-cell replication is regulated by commitment to differentiation. Over a lifetime of an organism, stem-cell clones compete in a tissue niche for Darwinian replicative advantages and in doing so accumulate mutations that permit stem-cell replication. Mutations in the p53 gene give stem cells this advantage, increase the clonal stem-cell population, and lower the age at which cancers can occur. Li-Fraumeni patients that inherit p53 mutations develop tumors in a tissue-type-specific fashion at younger ages. Throughout the life of a Li-Fraumeni patient, the tumor types that arise occur in tissues where stem cells are active and cell division is most rapid. Thus, p53 mutations that are inherited or occur during developmental life act in stem cells of the mesenchymal and epithelial lineages, whereas p53 mutations that occur in progenitor or differentiated (somatic) cells later in life function in tissues of endodermal origins, indicating that p53 may function differently in different developmental lineages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, recent studies have also assigned stem-cell maintenance functions to p53 (Cicalese et al. 2009;Levine et al. 2016), demonstrating that all three family members have similar functions in quality control in reproduction, stem-cell maintenance, and tumor suppression, albeit with different specializations acquired during evolution.”
From Structural Evolution and Dynamics of the p53 Proteins (2017) · cites this paper as Levine et al. 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 2×
“FUNCTION IN STEM CELLS A small number of humans and families harbor p53 mutations, which have been shown in 70% of the cases to be the cause of the Li–Fraumeni syndrome (Olivier et al. 2010).”
BackgroundSelf-citationOrganoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Defining the Epithelial Stem Cell Niche in Skin
Tumbar, T., Guasch, G., Greco, V., Blanpain, C., Lowry, W. E., Rendl, M., & Fuchs, E. (2004) · Science · doi:10.1126/science.1092436 · Cited by 2,031
Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver
Huch, M., Gehart, H., van Boxtel, R., Hamer, K., Blokzijl, F., Verstegen, M. M. A., Ellis, E., van Wenum, M., Fuchs, S. A., de Ligt, J., et al. (2015) · Cell · doi:10.1016/j.cell.2014.11.050 · Cited by 1,619
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration
Huch, M., Dorrell, C., Boj, S. F., van Es, J. H., Li, V. S. W., van de Wetering, M., Sato, T., Hamer, K., Sasaki, N., Finegold, M. J., et al. (2013) · Nature · doi:10.1038/nature11826 · Cited by 1,555
Suppression of induced pluripotent stem cell generation by the p53–p21 pathway
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., & Yamanaka, S. (2009) · Nature · doi:10.1038/nature08235 · Cited by 1,301
Linking the p53 tumour suppressor pathway to somatic cell reprogramming
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I. (2009) · Nature · doi:10.1038/nature08311 · Cited by 1,115
A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity
Marión, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., & Blasco, M. A. (2009) · Nature · doi:10.1038/nature08287 · Cited by 1,028 · cited 3×
“Remarkably, the absence of p53 in the fibroblasts being reprogrammed by these transcription factors permits the reprogramming of fibroblasts to iPS cells to occur with only SOX-2 and OCT-4, in a much higher percentage of the cells (10% to 80%) and in a much shorter time (a week) (Hong et al. 2009; Kawamura et al. 2009…”
BackgroundResult
Research works printed but not linked: 78
- 10.1073/pnas.0530291100 · DOI · Paper page
- 10.1073/pnas.1417322111 · DOI
- 10.1016/S0960-9822(95)00183-7 · DOI · Paper page
- 10.1038/cr.2014.165 · DOI · Paper page
- 10.1038/nature06196 · DOI · Paper page
- 10.1016/j.stem.2009.11.013 · DOI · Paper page
- 10.1038/8816 · DOI · Paper page
- 10.1101/cshperspect.a001198 · DOI · Paper page
- 10.1158/0008-5472.CAN-05-2018 · DOI · Paper page
- 10.1016/S0092-8674(00)81182-4 · DOI · Paper page
- 10.1038/sj.onc.1206929 · DOI
- 10.1101/gad.235473.113 · DOI · Paper page
- 10.1126/science.1065486 · DOI · Paper page
- 10.1038/356215a0 · DOI · Paper page
- 10.1101/gad.252148.114 · DOI
- 10.1002/ijc.27767 · DOI
- 10.1128/MCB.24.18.7987-7997.2004 · DOI · Paper page
- 10.1002/9780470151808.sc02f01s34 · DOI
- 1973, Nuclear transplantation and regulation of cell processes, Br Med Bull, 29, 259, 10.1093/oxfordjournals.bmb.a071017 · doi:10.1093/oxfordjournals.bmb.a071017
- 10.1155/S1110724304403131 · DOI · Paper page
- 10.1177/1947601909360812 · DOI
- 10.1101/gad.5.12b.2375 · DOI · Paper page
- 10.1200/JCO.2003.11.052 · DOI
- 10.1038/emboj.2013.204 · DOI · Paper page
- 10.1038/ncb2384 · DOI · Paper page
- 10.1038/83730 · DOI · Paper page
- 10.1371/journal.pbio.1001268 · DOI · Paper page
- 10.1038/ng747 · DOI · Paper page
- 10.1093/carcin/16.3.531 · DOI
- 10.1016/j.cell.2014.08.017 · DOI · Paper page
- 10.1016/S0092-8674(00)81333-1 · DOI · Paper page
- 10.1126/science.280.5366.1036 · DOI · Paper page
- 1964, Multipotentiality of single embryonal carcinoma cells, Cancer Res, 24, 1544
- 10.1038/nature12213 · DOI · Paper page
- 10.1016/j.stem.2012.05.020 · DOI
- 10.1073/pnas.1216922110 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-2030 · DOI · Paper page
- 10.1038/nature08290 · DOI · Paper page
- 10.1101/gad.8.10.1235 · DOI · Paper page
- 10.1101/SQB.1994.059.01.026 · DOI
- 10.1038/nm0796-804 · DOI · Paper page
- 10.1073/pnas.1117029108 · DOI · Paper page
- 10.1073/pnas.1017001108 · DOI · Paper page
- 10.1073/pnas.140208197 · DOI
- 10.1038/sj.onc.1207175 · DOI
- 10.1038/cr.2010.48 · DOI
- 10.1038/nature05372 · DOI · Paper page
- 10.1016/j.febslet.2006.07.004 · DOI
- 10.1371/journal.pone.0000782 · DOI
- 10.1242/dev.044297 · DOI · Paper page
- 10.1073/pnas.89.19.9064 · DOI · Paper page
- 10.1038/nbt1009-914 · DOI
- 10.1101/cshperspect.a026047 · DOI · Paper page
- 10.1038/nature05384 · DOI · Paper page
- 10.1038/nm966 · DOI · Paper page
- 10.1038/nature07935 · DOI · Paper page
- 10.1053/j.gastro.2011.07.050 · DOI · Paper page
- 10.1038/nature06489 · DOI · Paper page
- 10.1038/emboj.2012.149 · DOI · Paper page
- 10.1038/sj.cdd.4401539 · DOI · Paper page
- 10.1093/nar/gkn232 · DOI · Paper page
- 10.1016/0012-1606(74)90155-9 · doi:10.1016/0012-1606(74)90155-9
- 10.1023/A:1010615124301 · DOI · Paper page
- 10.1038/nature05337 · DOI · Paper page
- 1999, High susceptibility of a human breast epithelial cell type with stem cell characteristics to telomerase activation and immortalization, Cancer Res, 59, 6118
- 10.1016/j.cell.2007.11.019 · DOI · Paper page
- 10.1200/JCO.2009.22.7967 · DOI · Paper page
- 10.1126/science.1200801 · DOI · Paper page
- 10.1093/nar/gkn481 · DOI
- 10.1007/s100380200055 · DOI
- 10.1016/j.ctrv.2012.12.001 · DOI
- 10.1101/gad.1987810 · DOI
- 10.1038/sj.emboj.7601375 · DOI
- 10.1101/gr.6927808 · DOI
- 10.1038/90108 · DOI · Paper page
- 10.1158/1538-7445.AM2012-5635 · DOI
- 2014, Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells, Oncotarget, 5, 8924, 10.18632/oncotarget.2441 · DOI
- 10.1073/pnas.1310519110 · DOI
Cited by
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
Levine, A. J., Jenkins, N. A., & Copeland, N. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.11.009 · Cited by 121
Self-citationHaupt, S., Caramia, F., Herschtal, A., Soussi, T., Lozano, G., Chen, H., Liang, H., Speed, T. P., & Haupt, Y. (2019) · Nature Communications · doi:10.1038/s41467-019-13266-3 · Cited by 94
Structural Evolution and Dynamics of the p53 Proteins
Chillemi, G., Kehrloesser, S., Bernassola, F., Desideri, A., Dötsch, V., Levine, A. J., & Melino, G. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028308 · Cited by 65
Self-citationTP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited
Shin, D.-Y. (2023) · Cancers · doi:10.3390/cancers15194816 · Cited by 46
Metadata
- Authors
- Levine, A. J., Puzio-Kuter, A. M., Chan, C. S., & Hainaut, P.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-06-28
- Volume
- 6
- Issue
- 9
- Pages
- a026153
- ISSN
- 2157-1422
- Cited by
- 43
- References
- 14
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.